Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins.
about
Second-generation taxanes effectively suppress subcutaneous rat lymphoma: role of disposition, transport, metabolism, in vitro potency and expression of angiogenesis genesPotential for improvement of docetaxel-based chemotherapy: a pharmacological review.Population pharmacokinetics of intravenously and orally administered docetaxel with or without co-administration of ritonavir in patients with advanced cancer.Determination of docetaxel in rat plasma and its application in the comparative pharmacokinetics of Taxotere and SID530, a novel docetaxel formulation with hydroxypropyl-β-cyclodextrin.Novel formulations of taxanes: a review. Old wine in a new bottle?Pharmacokinetics, dynamics and toxicity of docetaxel: Why the Japanese dose differs from the Western dose.A critical review of lipid-based nanoparticles for taxane delivery.Dose modifications in Asian cancer patients with hepatic dysfunction receiving weekly docetaxel: A prospective pharmacokinetic and safety study.Docetaxel monotherapy as second-line treatment for pretreated advanced non-small cell lung cancer patients.Docetaxel-loaded PLGA and PLGA-PEG nanoparticles for intravenous application: pharmacokinetics and biodistribution profile.Metabolism of the taxanes including nab-paclitaxel.Treatment regimens of classical and newer taxanes.Bombesin-conjugated nanoparticles improve the cytotoxic efficacy of docetaxel against gastrin-releasing but androgen-independent prostate cancer.Impact of Dendrimers on Solubility of Hydrophobic Drug MoleculesDoceaqualip in a patient with prostate cancer who had an allergic reaction to conventional docetaxel: A case reportEffect of the excipient concentration on the pharmacokinetics of PM181104, a novel antimicrobial thiazolyl cyclic peptide antibiotic, following intravenous administration to mice.Determination of total and unbound docetaxel in plasma by ultrafiltration and UPLC-MS/MS: application to pharmacokinetic studies.Population pharmacokinetic and pharmacodynamic analysis for time courses of docetaxel-induced neutropenia in Japanese cancer patients.Comparison of adverse events following injection of original or generic docetaxel for the treatment of breast cancer.Significant effect of age on docetaxel pharmacokinetics in Japanese female breast cancer patients by using the population modeling approach.Open-label, randomized, single-dose, crossover study to evaluate the pharmacokinetics and safety differences between two docetaxel products, CKD-810 and Taxotere injection, in patients with advanced solid cancer.Localized delivery of curcumin into brain with polysorbate 80-modified cerasomes by ultrasound-targeted microbubble destruction for improved Parkinson's disease therapy.Safety of Polysorbate 80 in the Oncology Setting.Lessons learned from development of docetaxel
P2860
Q28574018-78D3E81B-6DD3-40DA-84DC-A282A80E3799Q33218801-100C8AB5-85ED-4871-B830-53B5354FF72FQ33795052-CCE1582C-0D3C-4E5D-AE2C-10A9D04ABB87Q34353491-27381D6B-9ED5-457B-8D9F-44BC8D16D24EQ34563540-0215AC52-B56C-48B0-893C-7C8080381A81Q35674153-8C735CA7-F699-4650-8967-0AECFB41B90FQ36360764-75A35DE3-936F-441C-88A1-20AC7C436478Q36622084-F41E400F-BF82-4738-88FA-AFDD11216EDDQ37205484-4676A81E-17F3-4E3A-AA79-16A8B700B40CQ37623841-76943621-E14F-4885-B596-DC1767773BC2Q38267987-E0CC11B2-7421-430D-98D7-C6942B7D52A1Q38641136-171F13CD-217A-47F8-A962-29E59F579D5EQ38834893-632C45BD-EC56-4FC1-A989-62FDB17E2562Q39339379-9062E7FD-E941-47F6-9F36-EF33F3C66189Q42183155-B9EFF309-2A9D-4CB9-93CC-241B824AAED0Q43173878-4C2CF0CB-4A93-48C4-8D3F-10E024866316Q45990964-DB49A56F-11B2-442B-91EA-B9983FA2B884Q46987657-CB0BC163-2773-4D87-A5BB-4E05966A06F2Q47281772-D227CD89-87A9-4D93-AE5A-30E43D6691BCQ50927629-BF787F9C-6A02-401B-BE6D-C880D085CF49Q54441195-A8131CD8-3F08-4B86-AFE5-82974DCED1C5Q55231878-6C1BF716-4623-4D30-ABF5-C370FE78C28FQ55405018-7D8C994A-D4EF-450D-893F-DEE5279B6469Q58382477-71C929D2-9A72-4AA9-9AB4-B05AD89BA8FD
P2860
Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins.
description
2003 nî lūn-bûn
@nan
2003 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Clinical pharmacokinetics of u ...... sorbate 80 and serum proteins.
@ast
Clinical pharmacokinetics of u ...... sorbate 80 and serum proteins.
@en
type
label
Clinical pharmacokinetics of u ...... sorbate 80 and serum proteins.
@ast
Clinical pharmacokinetics of u ...... sorbate 80 and serum proteins.
@en
prefLabel
Clinical pharmacokinetics of u ...... sorbate 80 and serum proteins.
@ast
Clinical pharmacokinetics of u ...... sorbate 80 and serum proteins.
@en
P2093
P1476
Clinical pharmacokinetics of u ...... sorbate 80 and serum proteins.
@en
P2093
Jaap Verweij
Joke G Boonstra
Sharyn D Baker
Walter J Loos
P304
P356
10.1016/S0009-9236(03)00222-4
P407
P577
2003-10-01T00:00:00Z